17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Androgen receptor; protein kinase DNA-activated catalytic polypeptide (PRKDC; DNAPK) Cell culture and mouse studies suggest inhibiting components of the...
07:00 , May 26, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Aptamer-small hairpin RNA chimeras for radiosensitization Aptamer-shRNA chimeras that decrease DNA repair activity in tumors could improve the efficacy of radiation...
07:00 , Mar 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Protein kinase DNA-activated catalytic polypeptide (PRKDC; DNAPK) In vitro studies suggest that a peptide inhibitor of PRKDC could help treat...